This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Synthetic Biologics Strengthens Research & Development Team To Support Expanding Pipeline Of Infectious Disease Therapies And Synthetic Biologics Programs

ROCKVILLE, Md., Oct. 23, 2012 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious diseases and unmet medical needs, announced today that Andrew Bristol, Ph.D., joined the team as its new Vice President of Research & Development. Dr. Bristol has over 20 years of experience in cancer research and drug development with a special emphasis on monoclonal antibodies and cancer vaccines. The Company also announced that Michael Kaleko, M.D., Ph.D., has been promoted to Senior Vice President of Research & Development.

Dr. Bristol comes to Synthetic Biologics after working with the National Institutes of Health (NIH) as a Post-doctoral Fellow, focusing on the development of cellular immunotherapy and anti-cancer vaccines. In 1998, he joined Genetic Therapy, Inc. (a Novartis company) and rose to the position of Senior Scientist & Deputy Program Head of the Immunology Program. In 2003, he co-founded Neogenix Oncology, a company focused on the discovery and product development using human cancer tissue extracts as starting material to generate anti-cancer monoclonal antibodies. He spent the next 10 years with Neogenix, leading the company to win numerous awards, including the 2010 Maryland Technology Council's "Emerging Company of the Year" award and the 2007 Frost & Sullivan "Excellence in Research" award. Prior to joining Synthetic Biologics, he was the Founder and General Manager of Bristol Consulting Services.

Dr. Bristol earned his Ph.D. degree from Tufts University, and his B.A. degree in Molecular Biology from the University of California, Berkeley.

Jeffrey Riley, Chief Executive Officer at Synthetic Biologics, stated, "We are pleased to welcome Andy to Synthetic Biologics and expect that his extensive knowledge and biotechnology experience – especially in the development of monoclonal antibodies and successfully navigating the drug development process – will be vital in moving our projects forward."

"Since Mike joined Synthetic Biologics he has been invaluable to us as we continue to expand our synthetic biologics and DNA-based human therapeutics research. He has been integral in ramping up both our synthetic DNA and monoclonal antibody programs with Intrexon," concluded Mr. Riley.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs